imm2902
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2022 (NCT05076591)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-23 receptorANTAGONIST
IL23R antagonist
- Receptor protein-tyrosine kinase erbB-2BINDING AGENT
ERBB2 binding agent
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05805956 | Phase 1/Phase 2 (Phase 2) | Feb 15, 2022 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd |
| NCT05076591 | Phase 1 | Jan 31, 2022 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd | For profit | 2 | 2 | 2 | 2022 |
1 organizations
Page 1 / 1